ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2017
High-precision radiotherapy for meningiomas : Long-term results and patient-reported outcome (PRO).
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.International journal of radiation oncology, biology, physics · 2020Trial
- Rational Radionuclide Therapy for Recurrent Meningioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Long-term outcomes and toxicity of radiotherapy for WHO Grade II and III meningiomas: a retrospective analysis of 98 patients.Journal of neuro-oncology · 2025Article
- The Rationale for Early Adjuvant Radiotherapy After Gross Total Resection of Atypical Meningioma.Neurosurgery · 2025Article
- Radiotherapy and radiosurgery for meningiomas.Neuro-oncology advances · 2023Article
- The Use of Photodynamic Therapy in the Treatment of Brain Tumors-A Review of the Literature.Molecules (Basel, Switzerland) · 2022Review
- High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas.BMC cancer · 2021Article
- Article
- Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome.European journal of nuclear medicine and molecular imaging · 2020Article
- Article
- Article
- Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis.Radiation oncology (London, England) · 2019Article
- Complementary medicine in radiation oncology : German health care professionals' current qualifications and therapeutic methods.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Article
- Influence ofRadiation oncology (London, England) · 2018Article
- Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning.Radiation oncology (London, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate long-term outcome after high-precision radiotherapy (RT) of meningioma patients in terms of survival and side effects.
methodsWe analyzed 275 meningioma cases: 147 low-grade and 43 high-grade meningiomas (WHO II: n = 40, III: n = 3). In all, 85 patients had no pathologically confirmed histology but were determined as low-grade based on multimodal imaging. Surgery was performed in 183 cases. RT was delivered as either radiosurgery (RS, n = 16), fractionated stereotactic radiotherapy (FSRT, n = 241), or intensity-modulated radiation therapy (IMRT, n = 18). Of 218 patients contacted for patient-reported-outcome (PRO), 207 responded (95%).
resultsMedian follow-up was 7.2 years. For low-grade meningioma the survival rate (OS) was 97% at 3 years, 85% at 10 years, and 64% at 15 years, for atypical meningioma 91% at 3 years, 62% at 10 years, and 50% at 15 years. Local control rate (PFS) for low-grade meningioma was 91% at 3 years, 87% at 5 years, and 86% at 10 years, for atypical cases 67% at 3 years and 55% at 5 years. Of all, 3.0% of patients reported worsened or new symptoms grade ≥3 during RT and the first 6 months thereafter; 17.5% reported a deterioration after more than 2 years. We found the prognostic factors tumor volume and age significantly influencing OS and PFS.
conclusionComplemented by PRO, we found long-term low toxicity rates in addition to excellent local control. Thus, due to the beneficial risk-benefit profile of benign and high-risk meningiomas, RT should be performed as adjuvant treatment and should not be postponed until tumor progression.
Indexed as
Identifiers
28620750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.